Revenue declined 1.2% year over year and rose 5.4% sequentially. Margins weakened from the previous quarter, indicating ongoing pressure on profitability. Year-over-year earnings remained under pressure, showing that the recovery in profitability is still incomplete.
Revenue remains weak year over year, but sequential improvement suggests near-term stabilization.
Margins deteriorated from last quarter, indicating weaker profit conversion.
Investor focus is likely to remain on whether management can restore earnings momentum over coming quarters.
Revenue trend and year-over-year growth across recent reported quarterly periods.
Net income and net margin trend over recent reported quarterly periods.
Pfizer Inc. reported $17.6B in revenue for Q4 2025, down 1.2% YoY and up 5.4% QoQ. The result suggests that although topline pressure remains, quarterly demand may be starting to stabilize.
Net income came in at $-1.6B, down 508.9% YoY and down 146.5% QoQ. Net margin was -9.4%. Sequential margin deterioration suggests profitability remains under pressure.
Quick factual answers for this report. Need the why behind them? Ask the report assistant.
Pfizer Inc. reported revenue of $17.6B in Q4 2025.
Pfizer Inc. reported net income of $-1.6B in Q4 2025.
Pfizer Inc.'s revenue decreased by 1.2% year over year in Q4 2025.
Pfizer Inc.'s net margin was -9.4% in Q4 2025.
Compare this quarter with the previous earnings report.
Explore company profile, industry, and historical context.
View more quarterly financial trend pages for this company.
Financial data is sourced from company filings and internal processed earnings data.
YoY and QoQ values are derived from reported quarterly figures when not directly available.
This page is for informational purposes only and does not constitute investment advice.